Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

To join this study, people generally need to be 18 or older and have a type of cancer that has spread locally or throughout the body. Crucially, your cancer must have one of those specific genetic changes we mentioned: NTRK, ROS1, or ALK gene fusions. Doctors will need to confirm this with a tissue sample from your cancer.

You might still be able to join even if your cancer has spread to your brain, as long as it's not causing serious symptoms or has been treated and is under control. You can also have had previous cancer treatments like chemotherapy or radiotherapy, but there are some rules about how long ago you finished them. For example, if you've had certain cancer-targeting drugs before, you might not be able to join, depending on the specific drug and your cancer type.

There are also general health requirements, like being well enough to carry out daily activities and having your organs (like your liver and kidneys) working properly. You must be able to swallow the study drug whole. The study cannot accept people who are currently in another medical study testing a new treatment.

If you join this study, you would receive the study drug, entrectinib. The study is open-label, meaning both you and your doctors would know you are receiving entrectinib. You would have regular appointments at the study clinic for assessments, which might include blood tests, scans, and physical exams to see how your cancer is responding and to check for any side effects. The exact schedule of visits and tests would be explained in detail by the study team. You would continue treatment for as long as it is helping you and you are tolerating it well. After stopping treatment, there would be follow-up appointments to monitor your health.